Piper Sandler Maintains Overweight on Black Diamond Therapeutic, Maintains $12 Price Target
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Joseph Catanzaro maintains an Overweight rating on Black Diamond Therapeutic (NASDAQ: BDTX) with a $12 price target.
July 03, 2024 | 4:28 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Piper Sandler analyst Joseph Catanzaro has reiterated an Overweight rating on Black Diamond Therapeutic (NASDAQ: BDTX) and maintained a $12 price target.
The reiteration of an Overweight rating and a $12 price target by a reputable analyst can boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100